onr:"swepub:oai:gup.ub.gu.se/325259"
Sökning: onr:"swepub:oai:gup.ub.gu.se/325259" > Effect of Disulfira...
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 11932naa a2200913 4500 | |
| 001 | oai:gup.ub.gu.se/325259 | |
| 003 | SwePub | |
| 008 | 240528s2023 | |||||||||||000 ||eng| | |
| 009 | oai:DiVA.org:oru-105313 | |
| 009 | oai:DiVA.org:uu-520223 | |
| 009 | oai:lup.lub.lu.se:434b5399-d57d-4f9f-91b5-0d3352a184bd | |
| 009 | oai:DiVA.org:liu-198092 | |
| 009 | oai:prod.swepub.kib.ki.se:153679759 | |
| 024 | 7 | a https://gup.ub.gu.se/publication/3252592 URI |
| 024 | 7 | a https://doi.org/10.1001/jamanetworkopen.2023.41492 DOI |
| 024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-1053132 URI |
| 024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5202232 URI |
| 024 | 7 | a https://lup.lub.lu.se/record/434b5399-d57d-4f9f-91b5-0d3352a184bd2 URI |
| 024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1980922 URI |
| 024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1536797592 URI |
| 040 | a (SwePub)gud (SwePub)orud (SwePub)uud (SwePub)lud (SwePub)liud (SwePub)ki | |
| 041 | a eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Werlenius, Katjau Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology,Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden,Sahlgrens Univ Hosp, Dept Oncol, Gothenburg, Sweden.;Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Dept Oncol, Gothenburg, Sweden.4 aut0 (Swepub:gu)xwerka |
| 245 | 1 0 | a Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma: A Randomized Clinical Trial. |
| 264 | c 2023-03-31 | |
| 264 | 1 | b American Medical Association (AMA),c 2023 |
| 500 | a Funding agencies:AG foundationSahlgrenska FoundationNordic Cancer UnionSwedish county councils concerning economic support of research and education of doctors (ALF-agreement) ALFGBG-716671 ALFGBG-933972 | |
| 500 | a Funding Agencies|Swedish government [ALFGBG-716671, ALFGBG-933972]; AG foundation; Sahlgrenska Foundation; Nordic Cancer Union; Swedish Society of Medicine [SLS-681721]; Swedish Cancer Society [CAN 2018/452]; Swedish county councils concerning economic support of research and education of doctors (ALF-agreement) [ALFGBG-716671, ALFGBG-933972] | |
| 520 | a Disulfiram has demonstrated broad antitumoral effect in several preclinical studies. One of the proposed indications is for the treatment of glioblastoma.To evaluate the efficacy and safety of disulfiram and copper as add-on to alkylating chemotherapy in patients with recurrent glioblastoma.This was a multicenter, open-label, randomized phase II/III clinical trial with parallel group design. Patients were recruited at 7 study sites in Sweden and 2 sites in Norway between January 2017 and November 2020. Eligible patients were 18 years or older, had a first recurrence of glioblastoma, and indication for treatment with alkylating chemotherapy. Patients were followed up until death or a maximum of 24 months. The date of final follow-up was January 15, 2021. Data analysis was performed from February to September 2022.Patients were randomized 1:1 to receive either standard-of-care (SOC) alkylating chemotherapy alone, or SOC with the addition of disulfiram (400 mg daily) and copper (2.5 mg daily).The primary end point was survival at 6 months. Secondary end points included overall survival, progression-free survival, adverse events, and patient-reported quality of life.Among the 88 patients randomized to either SOC (n=45) or SOC plus disulfiram and copper (n=43), 63 (72%) were male; the mean (SD) age was 55.4 (11.5) years. There was no significant difference between the study groups (SOC vs SOC plus disulfiram and copper) in 6 months survival (62% [26 of 42] vs 44% [19 of 43]; P=.10). Median overall survival was 8.2 months (95% CI, 5.4-10.2 months) with SOC and 5.5 months (95% CI, 3.9-9.3 months) with SOC plus disulfiram and copper, and median progression-free survival was 2.6 months (95% CI, 2.4-4.6 months) vs 2.3 months (95% CI, 1.7-2.6 months), respectively. More patients in the SOC plus disulfiram and copper group had adverse events grade 3 or higher (34% [14 of 41] vs 11% [5 of 44]; P=.02) and serious adverse events (41% [17 of 41] vs 16% [7 of 44]; P=.02), and 10 patients (24%) discontinued disulfiram treatment because of adverse effects.This randomized clinical trial found that among patients with recurrent glioblastoma, the addition of disulfiram and copper to chemotherapy, compared with chemotherapy alone, resulted in significantly increased toxic effects, but no significant difference in survival. These findings suggest that disulfiram and copper is without benefit in patients with recurrent glioblastoma.ClinicalTrials.gov Identifier: NCT02678975; EUDRACT Identifier: 2016-000167-16. | |
| 650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
| 650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
| 650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kirurgi0 (SwePub)302122 hsv//swe |
| 650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Surgery0 (SwePub)302122 hsv//eng |
| 653 | a Humans | |
| 653 | a Male | |
| 653 | a Middle Aged | |
| 653 | a Female | |
| 653 | a Glioblastoma | |
| 653 | a drug therapy | |
| 653 | a Copper | |
| 653 | a therapeutic use | |
| 653 | a Disulfiram | |
| 653 | a therapeutic use | |
| 653 | a Quality of Life | |
| 653 | a Antineoplastic Combined Chemotherapy Protocols | |
| 653 | a therapeutic use | |
| 700 | 1 | a Kinhult, Sarau Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Lund Univ, Sweden4 aut0 (Swepub:lu)onk-sk0 |
| 700 | 1 | a Solheim, Tora Skeidsvollu Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway; Cancer Clinic, St Olavs Hospital, Trondheim, Norway,Norwegian Univ Sci & Technol, Dept Clin & Mol Med, Fac Med & Hlth Sci, Trondheim, Norway.;St Olavs Hosp, Canc Clin, Trondheim, Norway.4 aut |
| 700 | 1 | a Magelssen, Henrietteu Department of Oncology, Oslo University Hospital, Oslo, Norway,Oslo Univ Hosp, Dept Oncol, Oslo, Norway.4 aut |
| 700 | 1 | a Löfgren, David,d 1977-u Örebro universitet,Institutionen för medicinska vetenskaper,Department of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden,Örebro Univ, Fac Med & Hlth, Dept Oncol, Örebro, Sweden.4 aut0 (Swepub:oru)dln |
| 700 | 1 | a Mudaisi, Munilau Karolinska Institutet,Linköpings universitet,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US,Finnmark Hosp, Norway4 aut0 (Swepub:liu)munmu89 |
| 700 | 1 | a Hylin, Sofiau Department of Neurology, Karolinska University Hospital, Stockholm, Sweden,Karolinska Univ Hosp, Dept Neurol, Stockholm, Sweden.4 aut |
| 700 | 1 | a Bartek, Jiriu Karolinska Institutet,Karolinska Institute,Karolinska University Hospital,Copenhagen University Hospital,Danish Cancer Society,Karolinska Univ Hosp, Sweden; Karolinska Inst, Sweden; Rigshosp, Denmark; Karolinska Inst, Sweden; Danish Canc Soc Res Ctr, Denmark4 aut |
| 700 | 1 | a Strandéus, Michaelu Department of Oncology, County Hospital Ryhov, Jönköping, Sweden,Cty Hosp Ryhov, Dept Oncol, Jönköping, Sweden.4 aut |
| 700 | 1 | a Lindskog, Magnusu Uppsala University,Uppsala universitet,Cancerprecisionsmedicin,Karolinska Univ Hosp, Dept Pelv Canc, Sect Genitourinary Oncol, Stockholm, Sweden.,Karolinska University Hospital,Uppsala Univ, Sweden; Karolinska Univ Hosp, Sweden4 aut0 (Swepub:uu)magli409 |
| 700 | 1 | a Rashid, Havyan Bahrozu Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden,Univ Gothenburg, Sahlgrenska Acad, Gothenburg, Sweden.4 aut |
| 700 | 1 | a Carstam, Louiseu Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap,Institute of Neuroscience and Physiology, Department of Clinical Neuroscience,Department of Neurosurgery, Sahlgrenska University Hospital, Gothenburg, Sweden; Institute of Neuroscience and Physiology, Department of Clinical Neuroscience, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden,Sahlgrens Univ Hosp, Dept Neurosurg, Gothenburg, Sweden.;Univ Gothenburg, Inst Neurosci & Physiol, Sahlgrenska Acad, Dept Clin Neurosci, Gothenburg, Sweden.4 aut0 (Swepub:gu)xcarsl |
| 700 | 1 | a Gulati, Sashau Department of Neurosurgery, St Olavs Hospital, Trondheim, Norway; Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway,St Olavs Hosp, Dept Neurosurg, Trondheim, Norway.;Norwegian Univ Sci & Technol, Dept Neuromed & Movement Sci, Trondheim, Norway.4 aut |
| 700 | 1 | a Solheim, Oleu Department of Neurosurgery, St Olavs Hospital, Trondheim, Norway; Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway,St Olavs Hosp, Dept Neurosurg, Trondheim, Norway.;Norwegian Univ Sci & Technol, Dept Neuromed & Movement Sci, Trondheim, Norway.4 aut |
| 700 | 1 | a Bartek, Jiri4 aut |
| 700 | 1 | a Salvesen, Øyvindu Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway,Norwegian Univ Sci & Technol, Dept Publ Hlth & Nursing, Trondheim, Norway.4 aut |
| 700 | 1 | a Jakola, Asgeir Storeu Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap,Institute of Neuroscience and Physiology, Department of Clinical Neuroscience,Department of Neurosurgery, Sahlgrenska University Hospital, Gothenburg, Sweden; Institute of Neuroscience and Physiology, Department of Clinical Neuroscience, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Neurosurgery, St Olavs Hospital, Trondheim, Norway,Sahlgrens Univ Hosp, Dept Neurosurg, Gothenburg, Sweden.;Univ Gothenburg, Inst Neurosci & Physiol, Sahlgrenska Acad, Dept Clin Neurosci, Gothenburg, Sweden.;St Olavs Hosp, Dept Neurosurg, Trondheim, Norway.4 aut0 (Swepub:gu)xjakas |
| 700 | 1 | a Salvesen, O4 aut |
| 710 | 2 | a Göteborgs universitetb Institutionen för kliniska vetenskaper, Avdelningen för onkologi4 org |
| 773 | 0 | t JAMA network opend : American Medical Association (AMA)g 6:3q 6:3x 2574-3805 |
| 856 | 4 | u https://doi.org/10.1001/jamanetworkopen.2023.4149y Fulltext |
| 856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:1826562/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
| 856 | 4 | u http://dx.doi.org/10.1001/jamanetworkopen.2023.4149x freey FULLTEXT |
| 856 | 4 | u https://liu.diva-portal.org/smash/get/diva2:1800097/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
| 856 | 4 8 | u https://gup.ub.gu.se/publication/325259 |
| 856 | 4 8 | u https://doi.org/10.1001/jamanetworkopen.2023.4149 |
| 856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-105313 |
| 856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-520223 |
| 856 | 4 8 | u https://lup.lub.lu.se/record/434b5399-d57d-4f9f-91b5-0d3352a184bd |
| 856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-198092 |
| 856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:153679759 |
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Werlenius, Katja
- Kinhult, Sara
- Solheim, Tora Sk ...
- Magelssen, Henri ...
- Löfgren, David, ...
- Mudaisi, Munila
- visa fler...
- Hylin, Sofia
- Bartek, Jiri
- Strandéus, Micha ...
- Lindskog, Magnus
- Rashid, Havyan B ...
- Carstam, Louise
- Gulati, Sasha
- Solheim, Ole
- Salvesen, Øyvind
- Jakola, Asgeir S ...
- Salvesen, O
- visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Cancer och onkol ...
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Kirurgi
- Artiklar i publikationen
- JAMA network ope ...
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
